Is This Under-the-Radar Growth Stock a Buy?
Concerns regarding inflation and future interest rate hikes by the Federal Reserve have caused the Nasdaq Composite to dip 12% year to date. But since this is a market of stocks rather than a stock market, many stocks have been hit much harder than the broader index.
The genetic-diagnostics company Veracyte (NASDAQ: VCYT) is one such stock. Veracyte has plunged 36% year to date. But is the growth stock a buy for investors? Let's dig into Veracyte's fundamentals and valuation to answer that question.
After a challenging year due to the COVID-19 pandemic, Veracyte emphatically rebounded in 2021.
Source Fool.com
